Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Une étude sur le nipocalimab pour réduire le risque de thrombopénie allo-immune fœtale et néonatale (FNAIT) (FREESIA-1)

2 novembre 2026 mis à jour par: Janssen Research & Development, LLC

Étude en double aveugle, randomisée et contrôlée par placebo évaluant l'innocuité et l'efficacité du nipocalimab dans la réduction du risque de thrombopénie allo-immune fœtale et néonatale (FNAIT) dans les grossesses à risque

The purpose of this study is to evaluate the effectiveness of nipocalimab compared with placebo in reducing the risk of severe fetal and neonatal alloimmune thrombocytopenia (FNAIT).

Aperçu de l'étude

Statut

Recrutement

Type d'étude

Interventionnel

Inscription (Estimé)

39

Phase

  • Phase 3

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

      • Leuven, Belgique, 3000
        • Complété
        • Universitair Ziekenhuis Leuven
      • Recife, Brésil, 50070-902
        • Complété
        • Instituto de Medicina Integral Professor Fernando Figueira
      • Rio de Janeiro, Brésil, 22281 100
        • Complété
        • IDOR - Regional Rio de Janeiro
      • São Paulo, Brésil, 05403 000
        • Complété
        • Hospital Das Clinicas Da Faculdade De Medicina Da USP
      • Seville, Espagne, 41013
        • Complété
        • Hosp. Virgen Del Rocio
      • Lille, France, 59000
        • Complété
        • CHRU Lille
      • Paris, France, 75012
        • Complété
        • Hopital trousseau- APHP
      • Budapest, Hongrie, 1082
        • Recrutement
        • Semmelweis Egyetem
      • Ramat Gan, Israël, 5262000
        • Complété
        • Sheba Medical Center
      • Milan, Italie, 20122
        • Complété
        • Mangiagalli Clinic IRCCS Ca Granda Foundation Ospedale Maggiore Policlinico
      • Rome, Italie, 00168
        • Complété
        • Fondazione Policlinico Universitario A Gemelli IRCCS
      • Bergen, Norvège, 5009
        • Recrutement
        • Haukeland University Hospital
      • Oslo, Norvège, 0455
        • Recrutement
        • Oslo University Hospital HF Ulleval sykehus
      • Tromsø, Norvège, 9019
        • Recrutement
        • Universitetssykehuset Nord-Norge HF
      • Trondheim, Norvège, 7030
        • Recrutement
        • St. Olavs Hospital
      • Košice, Slovaquie, 04190
        • Complété
        • Univerzitna nemocnica L. Pasteura Kosice
      • Martin, Slovaquie, 036 01
        • Complété
        • Univerzitná nemocnica Martin
      • Nové Zámky, Slovaquie, 940 34
        • Complété
        • Fakultna nemocnica s poliklinikou Nove Zamky
      • Ljubljana, Slovénie, 1000
        • Complété
        • Univerzitetni klinicni center Ljubljana
      • Lausanne, Suisse, 1011
        • Complété
        • Centre Hospitalier Universitaire Vaudois CHUV
      • Stockholm, Suède, SE-141 86
        • Recrutement
        • Karolinska Universitetssjukhuset Huddinge

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans à 45 ans (Adulte)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Femelle

La description

Inclusion Criteria:

  • Pregnant and an estimated gestational age (GA; based on ultrasound dating) from Week 13 to 18 at randomization
  • Has a history of greater than or equal to (>=) 1 prior pregnancy with fetal and neonatal alloimmune thrombocytopenia (FNAIT) (including neonatal platelet count less than (<) 150×10^9/Liter) with none of them affected by fetal/neonatal intracranial hemorrhage (ICH) or severe hemorrhage based on a clinical review of the medical records
  • Current pregnancy with presence of maternal anti- human platelet antigen (HPA)-1a alloantibody and positive fetal HPA-1a genotype as confirmed by cell-free fetal deoxyribonucleic acid (DNA) in maternal blood
  • Health status considered stable by the investigator based on physical examination, medical history, vital signs, 12-lead Electrocardiogram (ECG), and clinical laboratory tests performed at screening
  • For maternal participant and neonate/infant, willing to forego participation in another clinical study of an investigational therapy until the last follow-up visit

Exclusion Criteria:

  • Currently pregnant with multiple gestations (twins or more)
  • History of severe preeclampsia in a previous pregnancy
  • History of myocardial infarction, unstable ischemic heart disease, or stroke
  • Known allergies, hypersensitivity, or intolerance to nipocalimab or its excipients (refer to the Investigator Brochure (IB))
  • Has any confirmed or suspected clinical immunodeficiency syndrome or has a family history of congenital or hereditary immunodeficiency unless confirmed absent in the participant

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Double

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Comparateur actif: Nipocalimab

Maternal participants will receive nipocalimab Intravenously (IV).

Nipocalimab will be administered intravenously.

Autres noms:
  • JNJ-80202135
  • JNJ-86507083
Comparateur placebo: Placebo

Maternal participants will receive placebo IV.

Placebo will be administered intravenously.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Fetus/Neonate with Outcome of Death or Adjudicated Severe Bleeding or Platelet Count Less Than (<) 30*10^9/L
Délai: Up to 1 week post birth

Outcome of fetus/neonate death or adjudicated severe bleeding up to the first week post birth or platelet count <30*10^9/L will be reported.

Up to 1 week post birth

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Neonate/Fetus With Adjudicated Bleeding
Délai: Up to 1 Week post birth

Neonate/fetus With adjudicated bleeding will be reported.

Up to 1 Week post birth
Platelet Count at Birth in a Neonate
Délai: At birth

Platelet count at birth in a neonate will be reported.

At birth
Neonate/Fetus with Outcome of Death
Délai: Up to 1 Week post birth

Fetus/neonate with outcome of death will be reported.

Up to 1 Week post birth
Platelet Count at Birth <10×10^9/L in a Neonate
Délai: At birth

Platelet count at birth <10×10^9/L in a neonate will be reported.

At birth
Platelet Count at Birth <30×10^9/ L In a Neonate
Délai: At birth

Platelet count at birth <30×10^9/L in a neonate will be reported.

At birth
Platelet Count at Birth <50×10^9/L In a Neonate
Délai: At birth

Platelet count at birth <50×10^9/L in a neonate will be reported.

At birth
Platelet Count at Birth <150×10^9/L In a Neonate
Délai: At birth

Platelet count at birth <150×10^9/L in a neonate will be reported.

At birth
Nadir Platelet Count of a Neonate Over the First Week Post Birth
Délai: Upto 1 Week post birth

Nadir platelet count in a neonate will be reported.

Upto 1 Week post birth
Neonate/Fetus Requiring Platelet Transfusion(s)
Délai: Up to 1 Week post birth

Neonate(s) who require at least one platelet transfusion(s) will be reported.

Up to 1 Week post birth
Number of Platelet Transfusion(s) in Neonate/Fetus
Délai: Up to 1 Week post birth

Number of Platelet transfusion(s) per neonate will be reported.

Up to 1 Week post birth
Number of Donor Exposures for Platelet Transfusion(s) in Neonate/Fetus
Délai: Up to 1 Week post birth

Number of donor exposures for neonates who received platelet transfusion(s) will be reported.

Up to 1 Week post birth
Neonate/Fetus With Adjudicated Severe Bleeding
Délai: Up to 1 week post birth

Neonate/Fetus With adjudicated severe bleeding will be reported.

Up to 1 week post birth
Neonates With Postnatal Intravenous Immunoglobulin (IVIG) for The Treatment of Thrombocytopenia
Délai: Up to 1 Week post birth

Neonates with IVIG for the treatment of thrombocytopenia will be reported.

Up to 1 Week post birth
Maternal Participants With Treatment-Emergent Adverse Event (TEAE)
Délai: From randomization up to 24 weeks postpartum

Maternal participants with a TEAE will be reported. An adverse event (AE) is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the intervention under study. TEAEs are defined as AEs with onset or worsening on or after date of first dose of study treatment.

From randomization up to 24 weeks postpartum
Maternal Participants With Serious Adverse Event (SAE)
Délai: From randomization up to 24 weeks postpartum

Maternal participants with SAE will be reported. An adverse event (AE) is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the intervention under study. SAE is any untoward medical occurrence that at any dose that results in death, is life-threatening, requires inpatient hospitalization/prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect and is medically important.

From randomization up to 24 weeks postpartum
Maternal Participants With Adverse Event of Special Interest (AESI)
Délai: From randomization up to 24 weeks postpartum

Maternal participants with an AESI will be reported. An adverse event (AE) is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the intervention under study. AESIs are considered as infections that are severe, hypoalbuminemia, deep vein thrombosis and/or pulmonary embolism, and clinically significant bleeding.

From randomization up to 24 weeks postpartum
Maternal Participants with TEAE Leading to Discontinuation of Study Intervention
Délai: Up to Week 104

Maternal participants with TEAE leading to discontinuation of study intervention will be reported.

Up to Week 104
Neonate/Infant with TEAE
Délai: Up to Week 104

Neonatal/infant participants with a TEAE will be reported. An adverse event (AE) is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the intervention under study. TEAEs are defined as AEs with onset or worsening on or after date of first dose of study treatment.

Up to Week 104
Neonate/Infant with SAE
Délai: Up to Week 104

Neonatal/infant participants with SAE will be reported. An adverse event (AE) is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the intervention under study. An SAE is any untoward medical occurrence that at any dose that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect and is medically Important.

Up to Week 104
Neonate/Infant with AESI
Délai: Up to Week 104

Neonatal/infant participants with AESI will be reported. An adverse event (AE) is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the intervention under study. AESIs are considered as: In infants- clinically significant mortalities in fetus/neonates due to maternal infections, and hypogammaglobulinemia.

Up to Week 104
Fetus/Neonate With TEAE of Bleeding
Délai: Up to Week 104

Fetus/Neonate with TEAE of Bleeding will be reported. An adverse event (AE) is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the intervention under study. Treatment-emergent AEs are defined as AEs with onset or worsening on or after date of first dose of study treatment.

Up to Week 104
Neonate With TEAE of Infection
Délai: Up to Week 104

Neonate with TEAE of Infection will be reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the intervention under study. Treatment-emergent AEs are defined as AEs with onset or worsening on or after date of first dose of study treatment.

Up to Week 104
Infant Development as Measured by Bayley Scales at Week 52 and Week 104
Délai: At Week 52 and 104

The Bayley Scales of Infant and Toddler Development include a set of individually administered developmental scales designed to measure current developmental functioning in infants and toddlers up to 42 months of age in the areas of cognition, language, motor skills, social-emotional, and adaptive behavior, with age adjusted for prematurity. The cognition, language, motor skills scales are directly administered to the infant, while social-emotional, and adaptive behavior scales are caregiver questionnaires. The scores are standardized using norm reference samples with representative demographics and age adjusted for prematurity.

At Week 52 and 104
Maternal Participants With Antibodies to Nipocalimab Including Neutralizing Antibodies in Maternal Serum During Pregnancy and Postpartum
Délai: Up to Week 24

Maternal participants with antibodies to nipocalimab including neutralizing antibodies in maternal serum during pregnancy and postpartum will be reported.

Up to Week 24

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Directeur d'études: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

11 novembre 2024

Achèvement primaire (Estimé)

5 décembre 2029

Achèvement de l'étude (Estimé)

5 décembre 2029

Dates d'inscription aux études

Première soumission

4 juin 2024

Première soumission répondant aux critères de contrôle qualité

4 juin 2024

Première publication (Réel)

10 juin 2024

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

3 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

2 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • 80202135FNAIT3001
  • 80202135FNAIT3001 (Autre identifiant: Janssen Research & Development, LLC)
  • 2023-504307-88-00 (Identificateur de registre: EUCT number)
  • 2023 (Subvention/contrat des NIH des États-Unis)

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner